{"id":"NCT00433290","sponsor":"Eli Lilly and Company","briefTitle":"Duloxetine vs. Placebo in the Treatment of Osteoarthritis Knee Pain","officialTitle":"Protocol F1J-MC-HMFG Duloxetine 60 to 120 mg Versus Placebo in the Treatment of Patients With Osteoarthritis Knee Pain","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-02","primaryCompletion":"2008-05","completion":"2008-05","firstPosted":"2007-02-09","resultsPosted":"2009-08-24","lastUpdate":"2009-09-02"},"enrollment":256,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Osteoarthritis Knee Pain"],"interventions":[{"type":"DRUG","name":"Duloxetine","otherNames":["LY248686","Cymbalta"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"A","type":"EXPERIMENTAL"},{"label":"B","type":"PLACEBO_COMPARATOR"}],"summary":"The primary purpose of this study is to determine if duloxetine reduces pain severity in patients with osteoarthritis knee pain.","primaryOutcome":{"measure":"Change in Brief Pain Inventory (BPI) 24-hour Average Rating","timeFrame":"Baseline, Week 4, Week 7, Week 13","effectByArm":[{"arm":"Duloxetine","deltaMin":-1.8,"sd":0.16},{"arm":"Placebo","deltaMin":-1.12,"sd":0.15}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":7,"countries":["United States","Greece","Russia","Sweden"]},"refs":{"pmids":["31505082","24650448","22133624"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3},"commonTop":["Nausea","Constipation","Diarrhoea","Dizziness","Headache"]}}